RE Binx - They seem to have got the distribution rights with...

RE Binx - They seem to have got the distribution rights with no/immaterial up front payment, looking at the investment cashflow in the annual report. You can see how it could be valuable to get a cheap "roladex". If they paid up for it, then it would be more of an economic question.

From the annual report:
US Product Sales Channel
During the second half of FY2023, Lumos commenced activities directed at establishing a US sales channel for point-of-care
diagnostic tests. These activities include securing distribution rights for market-ready or in market products and establishing
a network of distributors and independent sales representatives. The sales channel will target the same physician offices
and urgent care clinics that are relevant for Lumos’ own products, including FebriDx and ViraDx. The additional test menu
offering will improve the relevance and efficiency of the sales channel and make it economically more attractive, particularly
in the early stages of developing Lumos’ own product portfolio. Lumos expects to earn industry-standard distribution margins
on the external party’s products that it sells through this channel.

In addition to its own products Lumos is focused on securing distribution rights for point-of-care products for women’s health,
STIs, and other infectious diseases. In May 2023, Lumos secured the distribution rights for CLIA-waived, molecular, point-
of-care tests for the rapid detection of chlamydia and gonorrhoea from Binx Health. Lumos intends to leverage this channel
to stimulate customer adoption and incorporate those same customers into its US sales strategy for FebriDx and ViraDx.